Diligence memo · auto-generated · as of July 2, 2026
Oncology Analytics, Inc.
Oncology Analytics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Oncology Analytics, Inc. operates in Pharma, based in Atlanta.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Oncology Analytics, Inc. has raised $53M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $25M on 2020-04-30.
Most recent recorded round closed around 2020-04-30.
Valuation (modeled)modeled
Provath models Oncology Analytics, Inc. at approximately $850M (range $52M–$3.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.18× the median modeled value of Series B Pharma companies in 2019–2021 (8 peers) — value vs value, same stage and era. Within the normal band (118% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 26 months.
Last raise 6.2 yr ago; this sector typically re-raises about every 16 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 85% of Pharma peers (310 compared).
Modeled value ranks above 89% of those peers.
Closest niche peers: Skincure Oncology Llc, Rescale, Inc., Small Pharma Financing Inc., Pasithea Therapeutics Corp., Kwivik Therapeutics, Inc..
Peoplefiled
21 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.